Clinical Trial Update: A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab [Phase 2]

View source ↗

Summary

Phase II study of nivolumab plus ipilimumab in advanced hepatocellular carcinoma patients who progressed on first-line atezolizumab plus bevacizumab was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED